Detalhe da pesquisa
1.
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.
Liver Int
; 44(4): 966-978, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38293761
2.
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
J Hepatol
; 79(5): 1110-1120, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37517454
3.
Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2.
Diabetes Obes Metab
; 23(3): 854-860, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33289297
4.
Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Diabetes Obes Metab
; 21(11): 2440-2449, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31264767
5.
Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study.
Hepatol Commun
; 8(1)2024 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38126958
6.
Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.
Diab Vasc Dis Res
; 18(1): 1479164121995928, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33611925
7.
Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone.
Diabetes Technol Ther
; 23(1): 70-77, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32721228
8.
Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.
Diabetes Technol Ther
; 23(1): 59-69, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32640846
9.
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Diabetes Care
; 43(11): 2713-2720, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32928957
10.
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Diabetes Technol Ther
; 21(9): 471-477, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31335194
11.
Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Diabetes Care
; 42(5): 919-930, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30833371
12.
HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Diabetes Care
; 41(9): 1981-1990, 2018 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-29937431
13.
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
Diabetes Care
; 41(9): 1970-1980, 2018 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-29937430